{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-25-000030","form_type":"8-K/A","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.302773+00:00","generated_at":"2026-05-23T00:11:17.240357+00:00","sec_items":["2.01","2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Travere Q1 2025 net product sales $75.9M, FILSPARI U.S. sales up 182% YoY; net loss narrows to $41.2M","bullets":["FILSPARI U.S. net product sales $55.9M in Q1 2025, up 182% YoY; 703 new patient start forms received.","Net loss of $41.2M ($0.47/share) vs $136.1M ($1.76) in Q1 2024; non-GAAP net loss $16.9M ($0.19).","sNDA for full approval of FILSPARI in FSGS submitted March 2025; FDA acceptance decision expected May 2025.","European Commission converted FILSPARI to standard MA for IgAN; expects $17.5M milestone from CSL Vifor in Q2 2025.","Cash, cash equivalents, and marketable securities $322.2M as of March 31, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-25-000030","json":"https://secwatch.observer/filing/0001438533-25-000030.json","markdown":"https://secwatch.observer/filing/0001438533-25-000030.md","text":"https://secwatch.observer/filing/0001438533-25-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853325000030/0001438533-25-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853325000030/tvtx-20250501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T00:11:17.240357+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}